Endvidere testede 6% af pædiatriske patienter seropositive mindst én gang under forsøget for antistoffer, der var i stand til at neutralisere de biologiske effekter af anakinra.
In addition, in a clinical trial 6% of paediatric patients tested seropositive at least once during the study for antibodies capable of neutralising the biologic effects of anakinra.